Result of AGM

RNS Number : 0015L
Hutchison China Meditech Limited
27 April 2020
 

 

Results of Annual General Meeting

 

 

London: Monday, April 27, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 27, 2020 were duly passed.  The poll results of the resolutions were as follows:

 


Number of Votes (%)*

 

Resolutions

 

For

 

 

Against

 

 

Withheld#

1

To consider and adopt the audited financial statements and the reports of the directors and independent auditor for the year ended 31 December 2019.

622,475,006

(99.97825%)

135,425

(0.02175%)

209,095


2(A)

To re-elect Mr Simon To as a director.

547,656,413

(93.79515%)

36,229,215

(6.20485%)

38,935,898


2(B)

To re-elect Mr Christian Hogg as a director.

614,200,226

(98.61822%)

8,605,840

(1.38178%)

15,460

 


2(C)

To re-elect Mr Johnny Cheng as a director.

612,394,636

(98.32808%)

10,412,825

(1.67192%)

14,065

 


2(D)

To re-elect Dr Weiguo Su as a director.

612,400,256

(98.32849%)

10,410,325

(1.67151%)

10,945






2(E)

To re-elect Dr Dan Eldar as a director.

612,014,066

(98.26647%)

10,796,615

(1.73353%)

10,845






2(F)

To re-elect Ms Edith Shih as a director.

612,006,786

(98.26611%)

10,798,775

(1.73389%)

15,965






2(G)

To re-elect Mr Paul Carter as a director.

620,440,741

(99.61989%)

2,367,325

(0.38011%)

13,460

 






2(H)

To re-elect Dr Karen Ferrante as a director.

622,577,316

(99.96253%)

233,365

(0.03747%)

10,845






2(I)

To re-elect Mr Graeme Jack as a director.

619,884,406

(99.53097%)

2,921,135

(0.46903%)

15,985






2(J)

To re-elect Professor Tony Mok as a director.

622,805,231

(99.99912%)

5,450

(0.00088%)

10,845






3

To re-appoint PricewaterhouseCoopers as the auditor of the Company and authorise the board of directors to fix the auditor's remuneration.

622,682,786

(99.97980%)

125,795

(0.02020%)

12,945






4

Ordinary Resolution No. 4(A)

:

To grant a general mandate to the directors of the Company to issue additional shares.

615,116,216

(98.76581%)

7,686,590

(1.23419%)

18,720







Special Resolution No. 4(B)

:

To disapply pre-emption rights (general power).

618,134,451

(99.25233%)

4,656,435

(0.74767%)

30,640







Special Resolution No. 4(C)

:

To disapply pre-emption rights (in connection with an equity raise).

529,841,459

(86.65474%)

81,598,207

(13.34526%)

11,381,860







Ordinary Resolution No. 4(D)

:

To grant a general mandate to the directors of the Company to repurchase shares of the Company.

622,786,026

(99.99584%)

25,890

(0.00416%)

9,610








5.

Ordinary Resolution

:

To amend the 2015 Share Option Scheme and refresh the scheme mandate limit under the 2015 Share Option Scheme.

501,381,220

(85.77268%)

83,165,305

(14.22732%)

38,275,001








6

Special Resolution

:

To adopt a new memorandum and articles of association of the Company.

622,545,861

(99.96014%)

248,265

(0.03986%)

27,400

 

*  Percentages rounded to 5 decimal places

# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

 

As at the date of the AGM, the number of issued shares of Chi-Med was 690,574,765, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolutions proposed at the AGM. 

 

About Chi-Med

 

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries


Mark Lee, Senior Vice President

+852   2121   8200

Annie Cheng, Vice President

+1   (973)   567   3786



Media Enquiries


Americas - Brad Miles, Solebury Trout

+1   (917)   570   7340   (Mobile) 
bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44   20   3727   1030 / +44   7771   913   902   (Mobile) / +44 7779 545 055 (Mobile)
Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852   9850   5033 (Mobile), jlo@brunswickgroup.com /

+852   97 83   6894 (Mobile), y zhou@brunswickgroup.com



Nominated Advisor


Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44   (20)   7886   2500

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEEFEWESSEIL
UK 100